NOVATO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride) and Naglazyme(R) (galsulfase) will be presented at the 11th Annual Meeting of the International Congress of Inborn Errors of Metabolism (ICIEM) in San Diego, California, August 29 through September 2, 2009.
